Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.

Annals of hematology - 1 Mar 2022

Kong Jinyu, Chen Nan, Li Mengyun, Zhang Jian, Wu Xiaoxia, Zong Lihong, Wu Depei, Song Baoquan, Qiu Huiying

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Bridged Bicyclo Compounds, Heterocyclic
Share to Decitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Share to Sulfonamides

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 33954816
DOI: 10.1007/s00277-021-04530-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.PMID 33954816Read ↗

Low-dose venetoclax, bortezomib, inotuzumab, rituximab, and dexamethasone (LoVe-BIRD) in a child with relapsed/refractory B-cell acute lymphoblastic leukemia with TP53 mutation.Semantic proximity Read ↗

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.Semantic proximity Read ↗

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemiaSemantic proximity Read ↗

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studySemantic proximity Read ↗

Haematological cancer: TP53 mutations sensitize to decitabine.Semantic proximity Read ↗

Short Course Venetoclax with standard chemotherapy is effective in Early T cell precursor acute lymphoblastic leukemiaSemantic proximity Read ↗

Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.Semantic proximity Read ↗

Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.Semantic proximity Read ↗

Obinutuzumab-induced coagulopathy in chronic lymphocytic leukaemia with trisomy 12.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.